TLDR Bakkt announced it will acquire stablecoin payments firm Distributed Technologies Research in an all-stock transaction. The acquisition is subject to regulatoryTLDR Bakkt announced it will acquire stablecoin payments firm Distributed Technologies Research in an all-stock transaction. The acquisition is subject to regulatory

Bakkt Confirms DTR Acquisition Plan, Stock Gains 10% Post-Announcement

TLDR

  • Bakkt announced it will acquire stablecoin payments firm Distributed Technologies Research in an all-stock transaction.
  • The acquisition is subject to regulatory and shareholder approval before completion.
  • Bakkt shares rose by approximately 10 percent following the acquisition announcement.
  • The deal is backed by Intercontinental Exchange which is Bakkt’s largest shareholder.
  • Bakkt plans to enhance its global stablecoin settlement and programmable payments platform through this acquisition.

Crypto services company Bakkt confirmed plans to acquire Distributed Technologies Research Ltd. (DTR) in an all-stock transaction, pushing its shares up 10% on Monday, with the deal contingent on both regulatory and shareholder approval, signaling an advancement in Bakkt’s strategy to build a unified global payments infrastructure.

Bakkt Strengthens Stablecoin Platform Through Acquisition

Bakkt announced it will fully acquire DTR, a stablecoin payments firm, through an all-stock transaction. The company stated that the deal remains subject to shareholder and regulatory approval.

The acquisition aims to enhance Bakkt’s global stablecoin settlement and programmable payments capabilities. The move also supports the firm’s expansion into payment and banking infrastructure.

Intercontinental Exchange, Bakkt’s largest shareholder, supports the transaction. This backing reflects confidence in the firm’s long-term roadmap.

CEO Akshay Naheta said the deal “realizes a long-term plan to create a single financial infrastructure platform globally.” He added that Bakkt will combine its regulatory base with DTR’s technology to serve merchants, institutions, and users.

Bakkt seeks to provide a seamless solution linking traditional finance compliance with the speed and flexibility of blockchain systems. The combined platform targets both cross-border payments and on-chain financial applications.

DTR’s ION Network to Boost Programmable Payments

In May 2025, Bakkt announced plans to integrate DTR’s ION Network into its regulated architecture. This integration focuses on stablecoin-based cross-border payments and AI-enabled programmable finance.

The ION Network supports blockchain-native infrastructure that simplifies global transactions. Its compatibility with compliance frameworks makes it suitable for financial institutions.

Bakkt stated the technology will play a key role in its programmable payments expansion. The company expects the unified system to bring new operational efficiencies.

Mike Alfred, a board member and part of the special committee, said the acquisition will “consolidate stablecoin settlement infrastructure.” He added it will prepare Bakkt for launching its neobanking model in the near term.

The company is engaging with multiple distribution partners to activate its neobanking rollout. Bakkt plans to scale this approach in the coming months.

Name Change and Market Focus Reinforce Growth Direction

Bakkt plans to change its corporate name to Bakkt, Inc. while keeping the ticker symbol ‘BKKT’ on the New York Stock Exchange. This name update aligns with its broader strategic direction.

The company originally started as a Bitcoin futures trading platform. Over time, it diversified into crypto payments and trading services.

The DTR acquisition reflects Bakkt’s focus on expanding its infrastructure for digital finance. This will include tools for merchants and institutions seeking scalable payment solutions.

The company emphasized that its platform will maintain strict compliance standards. This framework will help bridge centralized and decentralized systems effectively.

Bakkt confirmed that the acquisition supports its global ambitions. The firm is targeting growth beyond crypto-native markets.

The post Bakkt Confirms DTR Acquisition Plan, Stock Gains 10% Post-Announcement appeared first on CoinCentral.

Market Opportunity
GAINS Logo
GAINS Price(GAINS)
$0.01378
$0.01378$0.01378
+0.51%
USD
GAINS (GAINS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23